ImmunoGenesis Showcases Breakthrough Therapy for Glioblastoma at AACR 2026 ImmunoGenesis will highlight its innovative STING agonist therapy for glioblastoma at the 2026 AACR Annual Meeting in San Diego, showing promising preclinical results.

ImmunoGenesis Showcases Breakthrough Therapy for Glioblastoma at AACR 2026 #United_States #San_Diego #Glioblastoma #ImmunoGenesis #STING_Agonist